Max Healthcare Institute Limited announces that the Scheme of Amalgamation between Crosslay Remedies Limited and Jaypee Healthcare Limited has been officially sanctioned. The National Company Law Tribunal approved the merger, effective October 5, 2024. This strategic move consolidates Max Healthcare’s subsidiary operations, streamlining the group structure. The approval was granted on November 7, 2025.
Merger Sanctioned by Tribunal
The National Company Law Tribunal has officially approved the Scheme of Amalgamation involving Crosslay Remedies Limited and Jaypee Healthcare Limited, both wholly-owned subsidiaries of Max Healthcare Institute Limited. The order, received on November 7, 2025, signifies a key milestone in the company’s restructuring efforts.
Effective Date and Operational Changes
The appointed date for the amalgamation is set for October 5, 2024, as outlined in the approved scheme. With the sanction, Crosslay Remedies Limited will be dissolved without winding up, and its assets and liabilities will be integrated into Jaypee Healthcare Limited. All related contracts and employee agreements will transfer to Jaypee Healthcare, maintaining existing terms.
Scheme Details
The amalgamation scheme ensures the continuation of all legal and taxation proceedings. Further, the authorized share capital will also be adjusted. This merger streamlines the operations of Max Healthcare and is expected to bring efficiency to the overall organizational structure. With effect from the Effective Date, the Authorised Share Capital of the Company is INR 7,57,00,00,000.
Source: BSE
